VX-670 / Vertex, Entrada - LARVOL DELTA

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I (clinicaltrials.gov) - P2 | N=36 | Enrolling by invitation | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Genetic Disorders • Muscular Dystrophy • Myotonic Dystrophy

Myotonic Dystrophy Type 1 (DM1) (Vertex Press Release) - "Vertex is evaluating multiple approaches that target the underlying cause of DM1. Vertex’s lead approach, VX-670, is an oligonucleotide linked to a cyclic peptide, which holds the potential to address the underlying cause of DM1; Vertex continues to enroll and dose the MAD portion of the global Phase 1/2 clinical trial of VX-670 in people with DM1, which will assess both safety and efficacy."

Enrollment status • Myotonic Dystrophy

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated

New P2 trial • Genetic Disorders • Muscular Dystrophy • Myotonic Dystrophy

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Muscular Dystrophy • Myotonic Dystrophy

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (clinicaltrials.gov) - P1/2 | N=36 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated

New P1/2 trial • Genetic Disorders • Muscular Dystrophy • Myotonic Dystrophy